Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases

Reinfuss, Marian; Mituś, Jerzy; Smolak, K; Stelmach, Andrzej

doi:10.1016/0959-8049(93)90067-p

Cited by 65 publications

(39 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several histologic subtypes have been described using various classification systems. 2,4,5,9,17,18,24,25 However, these distinctions remain somewhat ambiguous and difficult to define. This is exemplified by the fact that although malignant tumors tend to be more aggressive both locally and distantly, metastases have been documented in patients with histologically benign tumors.…”

Section: Discussionmentioning

confidence: 99%

Primary treatment of cystosarcoma phyllodes of the breast

Chaney

Pollack

McNeese

et al. 2000

Cancer

353

361

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Primary treatment of cystosarcoma phyllodes of the breast

Chaney

Pollack

McNeese

et al. 2000

Cancer

353

361

View full text Add to dashboard Cite

“…[1][2][3][4][5] Histologic grade, [6][7][8] stromal overgrowth, 9,10 tumor necrosis and heterologous stromal elements, 11 as well as a combination of morphologic parameters, 12 have been traditionally used as predictors of clinical outcome. Nevertheless, specific parameters that can independently define recurrent likelihood are not universally agreed upon.…”

mentioning

confidence: 99%

p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study

et al. 2005

View full text Add to dashboard Cite

Breast phyllodes tumors are fibroepithelial neoplasms whose clinical behavior is difficult to predict on histology. There is relatively scant data on the role of biological markers. In this study, we determined if p53 and CD117 (c-kit) protein expression was predictive of behavior in a series of 335 phyllodes tumors diagnosed at the Singapore General Hospital, using immunohistochemistry on tissue microarrays. Representative areas from 250 (75%) benign, 54 (16%) borderline and 31 (9%) malignant phyllodes tumors were selected for construction of tissue microarrays using the 2 mm punch. Immunohistochemistry for p53 and CD117 was carried out using the streptavidin-biotin method. Staining proportion and intensity of both epithelial and stromal elements were analyzed. p53 immunostaining was observed in the epithelium of 28 (10%) of 278 microarrays; myoepithelium of 53 (21%) of 251 microarrays; and stromal cells in 105 (36%) of 289 microarrays. CD117 immunohistochemical reactivity was noted in epithelial and stromal components of 175 (of 267, 66%) and 17 (of 273, 6%) microarrays, respectively. Stromal p53 and CD117 protein expression was associated with tumor grade (Po0.05). Of 43 (13%) women who suffered recurrences during the follow-up period, CD117 stromal staining predicted recurrent disease (Po0.05), but p53 was not correlative. We conclude that tissue microarrays are a convenient method for evaluating immunostaining results of large numbers of phyllodes tumors. Although positive p53 stromal immunohistochemical detection may corroborate histologic malignancy, it is CD117 protein expression in phyllodes tumor stromal cells that may be of potential utility in predicting recurrent disease.

show abstract

“…The most common site of the initially diagnosed distant metastasis was the lungs. Other metastatic sites include the bones, liver, heart, and distant lymph nodes [23]. Rarely, direct extension without distant metastases may result in death [24,25].…”

Section: Discussionmentioning

confidence: 99%

Malignant Phyllodes Tumor of the Breast: A Case Report

Alzoubaidi

Qiu

Bonnen

et al. 2011

TOBCANJ

View full text Add to dashboard Cite

Phyllodes tumors of the breast have biphasic histological features with both epithelial and stromal components. Careful characterization of the stromal compartment is critical since it is the pathologic features of the stromal cells that determine its malignant potential. We present a case report of a woman with an aggressive malignant phyllodes tumor with sarcomatous differentiation, who succumbed to metastatic disease within 8 months of initial presentation.

show abstract

Malignant phyllodes tumours of the breast. A clinical and pathological analysis of 55 cases

Cited by 65 publications

References 25 publications

Primary treatment of cystosarcoma phyllodes of the breast

Primary treatment of cystosarcoma phyllodes of the breast

p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study

Malignant Phyllodes Tumor of the Breast: A Case Report

Contact Info

Product

Resources

About